Item #12
Overweight
Type 2’s Benefit Significantly From Orlistat
After
one year, patients lost 5.4% of their weight.
Treatment
with the lipase inhibitor orlistat in addition to a low calorie diet
significantly reduces weight of overweight patients with type 2
diabetes.
Glycemic control and cardiovascular risk factor profile are also
improved, report researchers in Dresden, Germany. Their multi-centre,
double-blind study assessed the long-term effects of orlistat in
overweight type 2 diabetics.
After a four-week lead-in period with placebo plus low calorie diet,
the researchers randomised 369 overweight or obese adults with
clinical type 2 diabetes to orlistat 120 mg. three times daily or
placebo, in conjunction with a low-calorie diet, for 48-weeks.
Study participants had body mass index of at least 28 kg/m² and HbA1c
of 6.5-11%. The patients were generally drug-naïve although a few did
receive sulphonylurea therapy for at least two months before the
study.
After one year, the 189 patients who had received orlistat lost 5.4%
of their weight, significantly more than the 180 patients on placebo
(3.6%). In addition, more than half of the patients (51.3%) lost 5% or
more weight. Fewer than a third (31.6%) of those given placebo did so.
Orlistat patients also had significantly greater improvements in
HbA1c, fasting glucose and postprandial glucose. Orlistat had the
further benefit of reducing low density lipoprotein cholesterol
significantly more than placebo.
The drug's safety profile was similar to placebo except for a higher
incidence of gastrointestinal side-effects known to be associated with
its mode of action. These side-effects were mostly mild and transient.
Diabetes,
Obesity & Metabolism 2002;4:6:415-423
===============================
Advertisement
dbaza
inc. has created a
comprehensive, practical, and engaging educational tool to educate
newly diagnosed children with type 1 diabetes.
This product can help you use
your education time more effectively, allowing you to spend your time
on the more difficult issues.
More
Information
[an error occurred while processing this directive]
|
